1Callahan MB, Lachance JA, Stone RL, et al. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol, 2007, 197 : 199-200.
2Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist, 2007, 12: 601-609.
3Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin reactions in cancer patients. Gynecol Oncol, 2006, 103 : 608-613.
5The National Comprehensive Cancer Network, Inc. 2009 NCCN clinical practice guidelines in oncology: ovarian cancer [ EB/ OL ]. [ 2009-9-24 ] . http://www, nccn. org/professionals/ physician_gls/f_guidelines, asp.
6Koshiba H, Hosokawa K, Kubo A, et al. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer, 2009, 19: 460-465.
7Hesterberg PE, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity : clinical presentation and management. J Allergy Clin Immunol, 2009, 123: 1262-1267.
8Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Alllergy Clin Immunol, 2008, 122, 574-580.
9Ollenschlager G et al. Recent Results Cancer Res,1991; 121:249-259
10Smale BF et al. Cancer, 1981; 47 (10): 2375-2381
